Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours

British Journal of Cancer

Volumn 101, Issue 4, 2009, Pages 645-657

  Ahlskog, J K J ^a   Schliemann, C ^a   Marlind J ^a   Qureshi, U ^b   Ammar, A ^b   Pedley, R B ^b   Neri, D ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CA IX; Carbonic anhydrase; Hypoxia; Phage display; Tumour targeting

Indexed keywords

CARBONATE DEHYDRATASE IX; ENZYME ANTIBODY; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY A3; HUMAN MONOCLONAL ANTIBODY CC7; MONOCLONAL ANTIBODY L19; PIMONIDAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ISOLATION; FEMALE; FLUORESCENCE MICROSCOPE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMAGE ANALYSIS; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; DIAGNOSTIC IMAGING; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASMS; T-PHAGES; TISSUE DISTRIBUTION;

EID: 68749119336     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605200     Document Type: Article

References (93)

1. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM (1998) Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 58: 485-490
2. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157
3. Ahlskog J, Dumelin CE, Trüssel S, Marlind J, Neri D (2009) In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett, e-pub ahead of print 13 June 2009; doi:1016/j.bmcl.2009.06.022
4. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL (2001) Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61: 5262-5267
5. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, Hilger CS, Cyr JE, Dinkelborg LM (2005) Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11: 7053s-7063s
6. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967-975
7. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102: 75-85
8. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102: 4384-4392
9. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M, Monneret C (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58: 1195-1201
10. Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12: 3200-3208
11. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 85: 1301-1307
12. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC (2004) Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45: 327-337
13. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357
14. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14: 154-169
15. Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, Neri D (2006) A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 5: 2083-2091
16. Cecchi A, Hulikova A, Pastorek J, Pastoreková S, Scozzafava A, Winum JY, Montero JL, Supuran CT. (2005) Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 48: 4834-4841
17. Chaplin DJ, Horsman MR, Siemann DW (2006) Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs 7: 522-528
18. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69: 358-368
19. Chrastina A, Pastorekova S, Pastorek J (2003a) Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. Neoplasma 50: 13-21
20. Chrastina A, Zavada J, Parkkila S, Kaluz S, Kaluzova M, Rajcani J, Pastorek J, Pastorekova S (2003b) Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 105: 873-881
21. Dearling JL, Flynn AA, Sutcliffe-Goulden J, Petrie IA, Boden R, Green AJ, Boxer GM, Begent RH, Pedley RB (2004) Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 45: 101-107
22. Demartis S, Tarli L, Borsi L, Zardi L, Neri D (2001) Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 28: 534-539
23. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67: 254-261
24. Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort MA, Pastoreková S, Scozzafava A, Wouters BG, Lambin P (2007) Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 83: 367-373
25. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ (1990) Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 50: 5531-5536
26. El Emir E, Qureshi U, Dearling JL, Boxer GM, Clatworthy I, Folarin AA, Robson MP, Nagl S, Konerding MA, Pedley RB (2007a) Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res 67: 11896-11905
27. El-Emir E, Dearling JL, Huhalov A, Robson MP, Boxer G, Neri D, van Dongen GA, Trachsel E, Begent RH, Pedley RB (2007b) Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer 96: 1862-1870
28. Fidarova EF, El-Emir E, Boxer GM, Qureshi U, Dearling JL, Robson MP, Begent RH, Trott KR, Pedley RB (2008) Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in meta-static colorectal cancer: implications for radioimmunotherapy. Clin Cancer Res 14: 2639-2646
29. Folkman J, Hahnfeldt P, Hlatky L (2000) Cancer: looking outside the genome. Nat Rev Mol Cell Biol 1: 76-79
30. Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E, Mulders PA, Merkx G, Figdor CG, Adema GJ, Oosterwijk E (2000) Molecular cloning and immuno-genicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85: 865-870
31. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2: 1394-1399
32. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515
33. Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jager D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G (2003) Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26: 44-48
34. Hoskin PJ, Sibtain A, Daley FM, Wilson GD (2003) GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89: 1290-1297
35. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051
36. Jankovic B, Aquino-Parsons C, Raleigh JA, Stanbridge EJ, Durand RE, Banath JP, MacPhail SH, Olive PL (2006) Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom 70: 45-55
37. Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM (2007) Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 67: 718-726
38. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739
39. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7: 3399-3403
40. Lavoie TB, Drohan WN, Smith-Gill SJ (1992) Experimental analysis by site-directed mutagenesis of somatic mutation effects on affinity and fine specificity in antibodies specific for lysozyme. J Immunol 148: 503-513
41. Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM (2009) Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel 22: 209-216
42. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA (2007) Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 67: 7646-7653
43. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399
44. Low PS, Henne WA, Doorneweerd DD (2008) Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41: 120-129
45. Mazure NM, Brahimi-Horn MC, Berta MA, Benizri E, Bilton RL, Dayan F, Ginouves A, Berra E, Pouyssegur J (2004) HIF-1: master and commander of the hypoxic world A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol 68: 971-980
46. Miller GK, Naeve GS, Gaffar SA, Epstein AL (1993) Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones. Hybridoma 12: 689-698
47. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5: 436-446
48. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65: 5907-5916
49. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, Stanbridge EJ (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61: 8924-8929
50. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J (1992) A novel quasi-viral agent, MaTu, is a two-component system. Virology 187: 620-626
51. Payne G (2003) Progress in immunoconjugate cancer therapeutics. Cancer Cell 3: 207-212
52. Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5: 172-179
53. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D (1998) Design and use of a phage display library Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273: 21769-21776
54. Pocker Y, Stone JT (1967) Catalytic versatility of erythrocyte carbonic anhydrase III kinetic studies of the enzyme-catalyzed hydrolysis of p-Nitrophenyl acetate. Biochemistry 6: 668-678
55. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443
56. Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58: 640-656
57. Rathmell WK, Chen S (2008) VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther 8: 63-73
58. Rybak JN, Trachsel E, Scheuermann J, Neri D (2007) Ligand-based vascular targeting of disease. Chem Med Chem 2: 22-40
59. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Durkop H, Menssen HD (2009) Expression of the oncofetal ED-B containing fibronectin isoform in hematologic tumors enables ED-B targeted 131I-L19SIP radioimmu-notherapy in Hodgkin's lymphoma patients. Blood 113: 2265-2274, e-pub 8 Jan 2009
60. Scheurer SB, Rybak JN, Rosli C, Neri D, Elia G (2004) Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: a transcriptomic and proteomic study. Proteomics 4: 1737-1760
61. Schliemann C, Neri D (2007) Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 1776: 175-192
62. Schnitzer JE (1998) Vascular targeting as a strategy for cancer therapy. N Engl J Med 339: 472-474
63. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147-159
64. Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, Viti F, Neri D (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5: 2340-2350
65. Silacci M, Brack SS, Spath N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D (2006) Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 19: 471-478
66. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P (2005) Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 65: 7259-7266
67. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425: 307-311
68. Street HH, Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ (2006) Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm 21: 243-256
69. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7: 168-181
70. Svastová E, Hulíková A, Rafajová M, Zat'ovicová M, Gibadulinová A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastoreková S (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577: 439-445
71. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood 94: 192-198
72. Thiry A, Dogne JM, Masereel B, Supuran CT (2006) Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 27: 566-573
73. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427
74. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA (2006) Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47: 1127-1135
75. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G (1992) The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 227: 776-798
76. van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO (1991) Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 48: 738-743
77. van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, Soede AC, McBride BJ, Goldenberg DM, Oyen WJ, Corstens FH, Boerman OC (2005) Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med 46: 495-501
78. Vaupel P (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206
79. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122: 2405-2413
80. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D (1999) Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 59: 347-352
81. von Lukowicz T, Silacci M, Wyss MT, Trachsel E, Lohmann C, Buck A, Luscher TF, Neri D, Matter CM (2007) Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med 48: 582-587
82. Walsh G (2006) Biopharmaceutical benchmarks 2006. Nat Biotechnol 24: 769-776
83. Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA (2008) Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J Nucl Med 49: 1828-1835
84. Weinmann M, Belka C, Plasswilm L (2004) Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 27: 83-90
85. Williams SC, Frippiat JP, Tomlinson IM, Ignatovich O, Lefranc MP, Winter G (1996) Sequence and evolution of the human germline V lambda repertoire. J Mol Biol 264: 220-232
86. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12: 433-455
87. Winter G, Harris WJ (1993) Humanized antibodies. Immunol Today 14: 243-246
88. Wu AM, Olafsen T (2008) Antibodies for molecular imaging of cancer. Cancer J 14: 191-197
89. Wu AM, Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23: 1137-1146
90. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158: 1011-1019
91. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083
92. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immuno-globulin forms. Cancer Res 52: 3402-3408
93. Zuberbühler K, Palumbo A, Bacci C, Giovannoni L, Sommavilla R, Kaspar M, Trachsel E, Neri D (2008) A general method for the selection of highlevel scFv and IgG antibody expression by stably transfected mammalian cells. Protein Eng Des Sel 22: 169-174